Trial Launches to Explore Using Virtual Reality to Treat Shortsightedness in Children

A new trial will determine the effectiveness of using virtual reality to treat myopia in children. The treatment combines the use of a VR headset with a phone app that is designed to stimulate dopamine releases in the retina.

The study, which is being conducted in the UK, will include 20 participants between the ages of 6 and 12.

In a press release, Dopavision’s CEO Mark Wuttke said, “We believe MyopiaX has the potential to be the first clinically validated myopia intervention that targets the eye’s dopamine pathway digitally. The MyopiaX-1 clinical trial is an important milestone for us, as it will provide the first clinical insights into our unique therapeutic approach to manage myopia. We are excited to see the trial launch in the UK and are delighted to have Lindus Health supporting us in this endeavor.”

Dopavision is a Berlin-based digital health start-up focused on developing therapeutic devices in ophthalmology.

“Working with Dopavision and other high-growth companies, we want to help find the next wave of breakthrough treatments,” said Lindus Health co-founder Michael Young in a press release. “Dopavision is a healthtech pioneer developing an exciting ophthalmology therapeutic that, delivered digitally, could have a huge impact on the lives of the rising number of children affected by childhood short-sightedness. We’re thrilled to be supporting their trial in the UK, using our own innovative technology platform that will help bring new treatments to patients more quickly.”